Baruch, Amos <br/><br/>
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subfractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study).  [electronic resource] 

 -  The American journal of cardiology  05 2017 
 - 1576-1583 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1879-1913 
<br/><br/><label>Standard No.: </label>10.1016/j.amjcard.2017.02.020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Biomarkers--blood<br/>Cholesterol, LDL--blood<br/>Coronary Disease--blood<br/>Cytokines--blood<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Inflammation--blood<br/>Injections, Subcutaneous<br/>Magnetic Resonance Spectroscopy<br/>Male<br/>Middle Aged<br/>Proprotein Convertase 9--immunology<br/>Risk Factors<br/>Young Adult